Sign in or create an account to add this stock to your watchlist.
About Miragen Therapeutics (NASDAQ:MGEN)
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan. The company also develops MRG-107, an inhibitor of miR-155 for treating neuronal amyotrophic lateral sclerosis, and other neurodegenerative indications, including spinal cord injury. It also develops preclinical product candidates for treating various indications, including oncology, visual pathologies, neurodegeneration, and hearing loss. Miragen Therapeutics, Inc. has a collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. The company was founded in 2006 and is based in Boulder, Colorado.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200
Debt
Debt-to-Equity Ratio0.14
Current Ratio20.91
Quick Ratio20.91
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales52.61
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book2.89
Profitability
EPS (Most Recent Fiscal Year)($1.38)
Net Income$-26,510,000.00
Net Margins-290.61%
Return on Equity-50.53%
Return on Assets-40.91%
Miscellaneous
Employees65
Outstanding Shares30,190,000
Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions
What is Miragen Therapeutics' stock symbol?
Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."
How were Miragen Therapeutics' earnings last quarter?
Miragen Therapeutics Inc. (NASDAQ:MGEN) posted its quarterly earnings data on Wednesday, May, 9th. The medical research company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. The medical research company had revenue of $4.78 million for the quarter, compared to analyst estimates of $1.17 million. Miragen Therapeutics had a negative return on equity of 50.53% and a negative net margin of 290.61%. View Miragen Therapeutics' Earnings History.
What price target have analysts set for MGEN?
9 brokerages have issued twelve-month price targets for Miragen Therapeutics' stock. Their predictions range from $13.00 to $29.00. On average, they expect Miragen Therapeutics' stock price to reach $17.1875 in the next year. View Analyst Ratings for Miragen Therapeutics.
What are Wall Street analysts saying about Miragen Therapeutics stock?
Here are some recent quotes from research analysts about Miragen Therapeutics stock:
- 1. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (5/16/2018)
- 2. Cann analysts commented, "MiRagen Therapeutics announced today positive new interim data from its phase I clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) will be presented on February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California. These positive results support MiRagen’s plans to initiate a phase II study of MRG-106 in CTCL in the second half of 2018. The data released today, along with the planned phase II trial design support our expectation that MRG-106 will be able to proceed to a registration phase II study, avoiding phase III trials." (2/2/2018)
Who are some of Miragen Therapeutics' key competitors?
Some companies that are related to Miragen Therapeutics include Natera (NTRA), RadNet (RDNT), Invitae (NVTA), CareDx (CDNA), Enzo Biochem (ENZ), Veracyte (VCYT), PotNetwork (POTN), Celcuity (CELC), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), OpGen (OPGN), Biocept (BIOC) and Cord Blood America (CBAI).
Who are Miragen Therapeutics' key executives?
Miragen Therapeutics' management team includes the folowing people:
- Mr. Bruce L. Booth Ph.D., D.Phil., Co-Founder & Chairman (Age 44)
- Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 54)
- Dr. Eric N. Olson Ph.D., Co-Founder and Member of Scientific Advisory Board
- Dr. Michael R. Bristow M.D., Ph.D., Co-Founder and Member of the Scientific Advisory Board (Age 73)
- Dr. Marvin H. Caruthers Ph.D., Co-Founder and Member of Scientific Advisory Board (Age 78)
Has Miragen Therapeutics been receiving favorable news coverage?
News stories about MGEN stock have been trending positive on Sunday, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Miragen Therapeutics earned a daily sentiment score of 0.42 on Accern's scale. They also gave media stories about the medical research company an impact score of 46.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Miragen Therapeutics' major shareholders?
Miragen Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (3.51%), BlackRock Inc. (2.68%), Artal Group S.A. (1.66%), Northern Trust Corp (0.57%), Dimensional Fund Advisors LP (0.54%) and CVI Holdings LLC (0.31%). Company insiders that own Miragen Therapeutics stock include Adam Scott Levy, Bruce Booth, Kyle Lefkoff and Thomas E Hughes. View Institutional Ownership Trends for Miragen Therapeutics.
Which institutional investors are buying Miragen Therapeutics stock?
MGEN stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Artal Group S.A., BlackRock Inc., Dimensional Fund Advisors LP, CVI Holdings LLC, Millennium Management LLC, Northern Trust Corp and Citadel Advisors LLC. Company insiders that have bought Miragen Therapeutics stock in the last two years include Adam Scott Levy and Bruce Booth. View Insider Buying and Selling for Miragen Therapeutics.
How do I buy shares of Miragen Therapeutics?
Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Miragen Therapeutics' stock price today?
One share of MGEN stock can currently be purchased for approximately $6.97.
How big of a company is Miragen Therapeutics?
Miragen Therapeutics has a market capitalization of $210.44 million and generates $4 million in revenue each year. The medical research company earns $-26,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Miragen Therapeutics employs 65 workers across the globe.
How can I contact Miragen Therapeutics?
Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]
MarketBeat Community Rating for Miragen Therapeutics (MGEN)
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Miragen Therapeutics (NASDAQ:MGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Miragen Therapeutics in the last 12 months. Their average twelve-month price target is $17.1875, suggesting that the stock has a possible upside of 146.59%. The high price target for MGEN is $29.00 and the low price target for MGEN is $13.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 2.89 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.1875 | $17.1875 | $17.90 | $23.00 |
| Price Target Upside: | 146.59% upside | 164.42% upside | 102.26% upside | 144.16% upside |
Miragen Therapeutics (NASDAQ:MGEN) Consensus Price Target History
Miragen Therapeutics (NASDAQ:MGEN) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Miragen Therapeutics (NASDAQ:MGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Miragen Therapeutics (NASDAQ MGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.90%
Institutional Ownership Percentage: 33.15%
Miragen Therapeutics (NASDAQ MGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/13/2018 | Adam Scott Levy | Insider | Buy | 9,090 | $5.50 | $49,995.00 | 10,540 |  |
| 2/13/2018 | Bruce Booth | Director | Buy | 545,454 | $5.50 | $2,999,997.00 | | |
| 12/20/2017 | Thomas E. Hughes | Director | Sell | 12,000 | $8.00 | $96,000.00 | | |
| 6/22/2017 | Adam Scott Levy | Insider | Buy | 200 | $7.55 | $1,510.00 | 200 | |
| 3/10/2017 | Kyle Lefkoff | Director | Sell | 5,800 | $14.34 | $83,172.00 | | |
| 3/8/2017 | Kyle Lefkoff | Director | Sell | 15,000 | $15.40 | $231,000.00 | | |
| 2/28/2017 | Kyle Lefkoff | Director | Sell | 10,258 | $13.89 | $142,483.62 | | |
| 2/23/2017 | Kyle Lefkoff | Director | Sell | 5,902 | $14.14 | $83,454.28 | | |
| 11/20/2015 | Samuel D. Riccitelli | CEO | Buy | 14,000 | $0.79 | $11,060.00 | 345,130 | |
(Data available from 1/1/2013 forward)
Miragen Therapeutics (NASDAQ MGEN) News Headlines
| Source: |
|
Miragen Therapeutics (NASDAQ:MGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Miragen Therapeutics (NASDAQ:MGEN) Income Statement, Balance Sheet and Cash Flow Statement
Miragen Therapeutics (NASDAQ MGEN) Stock Chart for Sunday, May, 27, 2018
Loading chart…
